Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002007 · ClinicalTrials.gov registry record · NA
A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia
A NA study, sponsored by Sandoz.
- Completed
- Registry status
- NA
- Development phase
NCT00002007 is a NA study that has completed, run by Sandoz.
The verdict
NCT00002007, a NA study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To evaluate the safety of repeated courses of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) administered subcutaneously to patients with HIV infection and leukopenia. To determine if administration of GM-CSF will prevent some or all of the hematologic toxicity associated with zidovudine ( AZT ) treatment in patients with pre-existing leukopenia. To assess any clinical and/or virologic benefits from administering alternating weeks of GM-CSF and AZT to patients with symptomatic HIV infection who have a history of cytologically confirmed Pneumocystis carinii pneumonia ( PCP ) or a circulating absolute CD4 lymphocyte count less than 200 cells/mm3.
Interventions
- DRUG Zidovudine
- DRUG Sargramostim
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002007
The ClinicalTrials.gov registry entry for NCT00002007 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002007 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002007 about?
NCT00002007 is a clinical study titled "A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia". To evaluate the safety of repeated courses of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) administered subcutaneously to patients with HIV infection and leukopenia. To determine if administration of GM-CSF will prevent some or all of the hematologic toxicity...
What is the current status of trial NCT00002007?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002007?
The interventions under investigation include: Zidovudine (DRUG), Sargramostim (DRUG).
Who is sponsoring clinical trial NCT00002007?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.